Aastrom Bio (ASTM) Grantd Key Australian Patent for Ixmyelocel-T

December 19, 2013 9:06 AM EST Send to a Friend
Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced that it has been granted a key composition-of-matter patent from the Australian Patent Office for ixmyelocel-T, Aastrom's cell therapy product candidate.

The issued patient, entitled "Mixed Cell Populations for Tissue Repair and Separation Technique for Cell Processing," provides protection for key characteristics of ixmyelocel-T through 2027. Aastrom now holds patent protection for ixmyelocel-T in Australia, the United States and the European Union.

"Patent approval in Australia expands our opportunity to commercialize ixmyelocel-T in multiple therapeutic markets and consider a range of partnership opportunities and other strategies to advance ixmyelocel-T through clinical development," said Nick Colangelo, president and chief executive officer at Aastrom Biosciences.

Aastrom is currently conducting the Phase 2b ixCELL-DCM clinical study of ixmyelocel-T in the United States and Canada for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy, a progressive disease of heart muscle and a leading cause of heart failure and heart transplantation.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA, Litigation, Management Comments

Add Your Comment